Evogene (EVGN) Current Deferred Revenue (2012 - 2025)
Evogene (EVGN) posted Current Deferred Revenue of -$361000.0 for Q4 2025, down 1.4% sequentially from -$356000.0 in Q3 2025, and down 200.28% YoY from $360000.0 in Q4 2024.
Evogene (EVGN) Current Deferred Revenue (2012 - 2025) Analysis & Trends
Evogene has reported Current Deferred Revenue for 14 years, with the latest figure at -$361000.0 in Q4 2025.
- Quarterly Current Deferred Revenue fell 200.28% year-over-year to -$361000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$361000.0 (down 200.28% YoY) and the FY2025 annual result came in at -$361000.0, up 35.42% from the prior year.
- Current Deferred Revenue declined to -$361000.0 in Q4 2025 per EVGN's latest filing, from -$356000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $742000.0 in Q3 2024 and troughed at -$478000.0 in Q4 2023.
- A 5-year average of $120400.0 and a median of $72500.0 in 2022 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue slumped 2272.73% in 2023, then jumped 1286.67% in 2024.
- Over 5 years, Current Deferred Revenue stood at $175000.0 in 2021, then sank by 87.43% to $22000.0 in 2022, then plunged by 2272.73% to -$478000.0 in 2023, then surged by 175.31% to $360000.0 in 2024, then slumped by 200.28% to -$361000.0 in 2025.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered -$361000.0, -$356000.0, and -$351000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -361,000.00 |
| Sep 30, 2025 | -356,000.00 |
| Jun 30, 2025 | -351,000.00 |
| Mar 31, 2025 | 209,000.00 |
| Dec 31, 2024 | 360,000.00 |
| Sep 30, 2024 | 742,000.00 |
| Jun 30, 2024 | 548,000.00 |
| Mar 31, 2024 | 416,000.00 |
| Dec 31, 2023 | -478,000.00 |
| Sep 30, 2023 | 739,000.00 |
| Jun 30, 2023 | 392,000.00 |
| Mar 31, 2023 | 30,000.00 |
| Dec 31, 2022 | 22,000.00 |
| Sep 30, 2022 | 360,000.00 |
| Jun 30, 2022 | -159,000.00 |
| Mar 31, 2022 | 115,000.00 |
| Dec 31, 2021 | 175,000.00 |
| Sep 30, 2021 | -47,000.00 |
| Jun 30, 2021 | 26,000.00 |
| Mar 31, 2021 | 26,000.00 |